A Randomized Clinical Trial of Immunization With...

A Randomized Clinical Trial of Immunization With Combined Hepatitis A and B Versus Hepatitis B Alone for Hepatitis B Seroprotection in Hemodialysis Patients

Abstract

BACKGROUND: The Centers for Disease Control and Prevention recommend immunizing susceptible high-risk groups, such as hemodialysis patients, against hepatitis B virus. However, hemodialysis patients may not develop seroprotective antibodies despite receiving high doses of the vaccine. Recent reports indicate that combined vaccination against hepatitis B and hepatitis A viruses may improve the immunogenicity of hepatitis B vaccine in healthy individuals, but the effectiveness of this strategy in hemodialysis patients is unknown. STUDY DESIGN: Prospective randomized controlled trial. SETTING & PARTICIPANTS: Hepatitis B virus-seronegative hemodialysis patients with undetectable antibody levels at baseline. INTERVENTION: Intramuscular administration of Twinrix (inactivated hepatitis A virus [720 ELISA units] and purified hepatitis B virus surface antigen [20 μg]; GlaxoSmithKline) and Engerix-B (purified hepatitis B virus surface antigen [20 μg]) at 0, 1, and 6 months plus Engerix-B, 40 μg, at month 2 (intervention arm) or Engerix-B, 40 μg, at 0, 1, 2, and 6 months (control arm). Both groups received a total dose of 160 μg of hepatitis B antigen. OUTCOMES: The primary outcome was the difference in seroprotection rates at 7 months, defined by antibody titers >10 mIU/mL. The secondary outcome was frequency of adverse events. MEASUREMENTS: Antibody response at months 3 and 7. RESULTS: 96 patients were enrolled, and 73 completed the investigation. At 3 months, there was no difference in the groups' seroprotection rates (25% vs 27%; P = 0.4). At the completion of the vaccination series, using per-protocol analysis, 27 of 40 (68%) and 16 of 33 (49%) had antibody titers >10 mIU/mL in the treatment and control groups, respectively (P = 0.05; RR, 1.4; absolute abatement, 19%). Intention-to-treat analysis showed 58% and 38% seroprotection rates in the treatment and control groups, respectively (P = 0.02; RR, 1.5; absolute abatement, 20%). There was no difference in adverse events. LIMITATIONS: Lack of evidence of long-term protection. CONCLUSION: Vaccination of hemodialysis patients with a combined hepatitis A and hepatitis B regimen resulted in a statistically significant and clinically important improvement in seroprotection against hepatitis B virus compared with hepatitis B monovalent vaccine.

Authors

Tung J; Carlisle E; Smieja M; Kim PT; Lee CH

Journal

American Journal of Kidney Diseases, Vol. 56, No. 4, pp. 713–719

Publisher

Elsevier

Publication Date

October 1, 2010

DOI

10.1053/j.ajkd.2010.04.015

ISSN

0272-6386

Associated Experts

Marek Smieja

Professor, Faculty of Health Sciences

Visit profile

Labels

A Randomized Clinical Trial of Immunization With Combined Hepatitis A and B Versus Hepatitis B Alone for Hepatitis B Seroprotection in Hemodialysis Patients

Abstract

Authors

Journal

Publisher

Publication Date

DOI

ISSN

Associated Experts

Labels

Fields of Research (FoR)

Sustainable Development Goals (SDG)

Medical Subject Headings (MeSH)

Contact the Experts team